Hikal Ltd.
NSE: HIKAL | BSE: 524735
₹180.10
₹0.32
(0.18%)
As on 09-Jun-2026 14:34IST
Market cap
₹2,211 Cr
Revenue (TTM)
₹1,713 Cr
P/E Ratio
--
P/B Ratio
1.8
Div. Yield
0.3 %
Quality Score
3/10
Growth Score
7/10
Valuation Score
4/10
Momentum Score
1/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-49 Cr
-
ROE
7.4 %
-
ROCE
9.9 %
-
Industry P/E
45.14
-
EV/EBITDA
12.4
-
Debt to Equity
0.3
-
Book Value
₹97.2
-
EPS
₹4.6
-
Face value
2
-
Shares outstanding
123,300,750
10 Years Aggregate
CFO
₹2,263.58 Cr
EBITDA
₹2,708.23 Cr
Net Profit
₹906.08 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Hikal
| -20.6 | -14.5 | -0.8 | -51.6 | -17.1 | -18.4 | 5.9 |
|
BSE Healthcare
| 8.6 | 1.3 | 8.3 | 9.1 | 24.9 | 13.5 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Hikal
| -43.7 | 30.1 | -25.9 | -22.1 | 215.6 | 41.4 | -26.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Hikal
|
180.1 | 2,211.4 | 1,712.6 | -48.8 | 3.3 | 4.8 | -- | 1.8 |
| 3,183.0 | 26,473.9 | 1,339.4 | 356.4 | 33.2 | 23.2 | 74.3 | 16.0 | |
| 429.8 | 16,494.4 | 2,268.6 | 150.1 | 10.6 | 5.4 | 92 | 4.2 | |
| 762.4 | 19,066.7 | 5,365.6 | 595.0 | 16.6 | 13.3 | 32 | 3.7 | |
| 965.5 | 15,284.6 | 8,279.6 | 397.8 | 9.9 | 6.4 | 38.4 | 2.2 | |
| 870.9 | 15,473.3 | 4,078.3 | 1,371.9 | 30.2 | 15.9 | 10.9 | 1.7 | |
| 1,724.5 | 19,648.0 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.4 | |
| 168.4 | 22,526.4 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.8 | |
| 444.5 | 17,995.6 | 3,738.7 | 316.7 | 12.5 | 7.5 | 56.8 | 3.7 | |
| 1,880.6 | 30,808.5 | 3,373.0 | 199.0 | 12.6 | 5.9 | 144.6 | 6.2 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Hikal
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in... India. The company operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. It also collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. In addition, the company offers human health products, such as anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-hypertensive, anti-inflammation, and analgesic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. It also exports its products. The company operates in the United States, Canada, Europe Union, Japan, Latin America, and internationally. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India. Read more
-
Incorporated
1988
-
Chairman
Jai Hiremath
-
Managing Director
Sameer Hiremath
-
Group
Kalyani
-
Headquarters
Mumbai, Maharashtra
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsCorporate Action-Board approves Dividend
27-May-2026Announcement Under Regulation 30 (LODR)- Updates
27-May-2026No News & Announcements are available.
FAQs for Hikal
What is the current share price of Hikal Ltd Today?
The share price of Hikal Ltd is ₹180.10 (NSE) and ₹180.35 (BSE) as of 09-Jun-2026 14:34 IST. Hikal Ltd has given a return of -17.13% in the last 3 years.
What is the current PB & PE ratio of Hikal Ltd?
Since, TTM earnings of Hikal Ltd is negative, P/E ratio is not available.
The P/B ratio of Hikal Ltd is 1.84 times as on 09-Jun-2026, a 53 discount to its peers’ median range of 3.90 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
54.42
|
3.91
|
|
2024
|
46.99
|
2.75
|
|
2023
|
44.34
|
3.07
|
|
2022
|
30.92
|
4.65
|
|
2021
|
13.29
|
1.90
|
What is the 52 Week High and Low of Hikal Ltd?
The 52-week high and low of Hikal Ltd are Rs 386.25 and Rs 146.25 as of 09-Jun-2026.
What is the market cap of Hikal Ltd?
Hikal Ltd has a market capitalisation of ₹ 2,211 Cr as on 09-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Hikal Ltd?
Before investing in Hikal Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.